# AP3 Rec'd PCT/PTO 11 MAY 2005

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMENCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES	ATTORNEY'S DOCKET NUMBER 700953-53666					
DESIGNATED/ELECTED OFFICE (DO/EO/US)	U.S. APPUCATION NO. (If known, see 37 CFR 1.5)					
CONCERNING A SUBMISSION UNDER 35 U.S.C. 371  INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED					
PCT/US2004/037810 12 November 2004 (12.11.2004)	. 12 November 2003 (12.11.2003)					
TITLE OF INVENTION SYSTEM FOR TREATING AND PREVENTING BRI	EAST CANCER					
APPLICANT(S) FOR DO/EO/US Therion Biologics Corporation, et al.						
Applicant herewith submits to the United States Designated/Elected Office (DO/EC	D/US) the following items and other information:					
1. X This is a FIRST submission of items concerning a submission under 35 U.S.C. 37	1.					
2. This is a SECOND or SUBSEQUENT submission of items concerning a submission	n under 35 U.S.C. 371.					
This is an express request to begin national examination procedures (35 U.S.C. 37 (5), (6), (9) and (21) indicated below.	71(f)). The submission must include items					
4. X The US has been elected (Article 31).	· •					
5. X A copy of the International Application as filed (35 U.S.C. 371(c)(2))						
a. is attached hereto (required only if not communicated by the Internation	nal Bureau).					
<ul> <li>b. has been communicated by the International Bureau.</li> </ul>						
c. $\overline{\mathbf{X}}$ is not required, as the application was filed in the United States Receive	V					
6. An English language translation of the International Application as filed (35 U.S.	C. 371(c)(2)).					
a. is attached hereto.						
b. has been previously submitted under 35 U.S.C. 154(d)(4).	`					
7. Amendments to the claims of the International Application under PCT Article 19	(35 U.S.C. 371(c)(3))					
a. are attached hereto (required only if not communicated by the International	ational Bureau).					
b. have been communicated by the International Bureau.	b. have been communicated by the International Bureau.					
c. have not been made; however, the time limit for making such amend	c. have not been made; however, the time limit for making such amendments has NOT expired.					
d. have not been made and will not be made.						
8. An English language translation of the amendments to the claims under PCT A	rticle 19 (35 U.S.C. 371(c)(3)).					
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).						
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).						
Items 11 to 20 below concern document(s) or information included:						
11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98.						
12. An assignment document for recording. A separate cover sheet in compliance v	with 37 CFR 3.28 and 3.31 is included.					
13. X A preliminary amendment.						
14. X An Application Data Sheet under 37 CFR 1.76.	·					
15. A substitute specification.	¥1					
16. A power of attorney and/or change of address letter.						
17. X A computer-readable form of the sequence listing in accordance with PCT Rule	e 13 <i>ter.</i> 2 and 37 CFR 1.821- 1.825.					
18. A second copy of the published International Application under 35 U.S.C. 154(						
19. A second copy of the English language translation of the international application	on under 35 U.S.C. 154(d)(4).					

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## IAP20 Rec'd PCT/PTO 11 MAY 2006

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ICATION NO. (#knews sep370 PRst.5)

INTERNATIONAL APPLICATION NO.

U.S. APPLICAT	be assign		PCT/US2004		700953-53	
20. Other items or information: Exp. Mail Cert. EV653005037US; COPY-Cert. of Limited Recognition; ORIGINAL-Statement Accompanying Seq. Listing; ORIGINAL-Seq. Listing; ORIGINAL-CRF; Statement Accompanying Substitute Seq. Listing; PAPER COPY-Substitute Seq. Listing; Substitute-CRF; COPY-Assignment from Parent; COPY-Int'l Search Report; COPY-References B1 and C1-C6 and Return Receipt Postcard.						
The follo	owing fees have b	een submitted			CALCULATIONS	PTO USE ONLY
				\$300	\$ 300.00	
22. X Examination fee (37 CFR 1.492(c))						
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)\$0 All other situations\$200				\$ 200.00		
23. X Search fee (37 CFR 1.492(b))  If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)\$0  Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority				\$ 100.00	·	
TOTAL OF 21, 22 and 23 =			600.00			
sequenc electroni	e for specification e listing in compli c medium) (37 CF	and drawings file ance with 37 CFR R 1.492(j)). dditional 50 sheet Number of each	d in paper over 100 sheets (e) 1.821(c) or (e) or computer pr s of paper or fraction thereof.  additional 50 or fraction	coluding ogram listing in an RATE		
	1	thereof (round up to a whole number)		\$ 0.00		
99 - 100 =	-1 /50 =			x \$250	\$	
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).			\$ 130.00			
CLAIMS	NUMI	BER FILED	NUMBER EXTRA	RATE	\$	
Total claims	43	- 20 =	23	x \$ 50	\$ 1,150.00	
Independent clai	ms {	- 3 =	5	x \$200	\$ 1,000.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360				\$ 0.00		
			TOTAL OF ABOVE		\$ 2,880.00	
Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.			0.00			
		<del> </del>		SUBTOTAL =	\$ 2,880.00	
Processing fee of claimed priority of	of <b>\$130.00</b> for furn date (37 CFR 1.49	ishing the English 92(i)).	translation later than 30 mont	ns from the earliest	\$	0.00
TOTAL NATIONAL FEE =			\$	2,880.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$	0.00		
TOTAL FEES ENCLOSED =			\$	2,880.00		
				<del></del>	Amount to be refunded:	\$
		<u> </u>			Amount to be charged	\$

10/579007

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		888		
a. 🗌	A check in the amount of \$	AP20 CO PCT/PTO 11 MAY 2006 to cover the above fees is enclosed.		
	Please charge my Deposit Account No. $\underline{50\text{-}0850}$ A duplicate copy of this sheet is enclosed.	_ in the amount of \$ _2,880.00 to cover the above fees.		
c. 🗴 🤾	The Commissioner is hereby authorized to charge any Account No50-0850 A duplicate copy of this sh	y additional fees which may be required, or credit any overpayment to Deposit sheet is enclosed.		
d. 🔲	Fees are to be charged to a credit card. WARNING: In be included on this form. Provide credit card information	Information on this form may become public. Credit card Information should not nation and authorization on PTO-2038.		
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.				
SEND AL Ronald Nixon 100 Su	L CORRESPONDENCE TO: I I. Eisenstein Peabody LLP Immer Street I, MA 02110	SIGNATURE Ronald I. Eisenstein/Leena H. Karttunen NAME 30,628 REGISTRATION NUMBER		

#### **!AP20Rec'd PCT/PTO** 11 MAY 2006

Practitioner's Docket No. 700953-53666

IN THE UNITED STATES RECEIVING OFFICE

International Application Number	International Filing Date	International Earliest Priority Date
PCT/US2004/037810	12 November 2004 (12.11.2004)	12 November 2003 (12.11.2003)

TITLE OF INVENTION:

SYSTEM FOR TREATING AND PREVENTING BREAST

CANCER

APPLICANT FOR DO/US:

THERION BIOLOGICS CORPORATION, et al.

## VERIFIED CERTIFICATION OF EXPRESS MAILING DATE (INTERNATIONAL APPLICATION (37 C.F.R. section 1.10(c))

I declare that, on May 11, 2006 I deposited, with the United States Postal Service, in an envelope "Express Mail, Post Office to Addressee," bearing Label Number EV653005037US, addressed to the "MAIL STOP PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450," and having an express mail certification that I executed, the following papers:

- 1. Express Mail Certificate EV653005037US (1 pg.);
- 2. COPY-Certificate of Limited Recognition (1 pg.);
- 3. Transmittal Letter Under 35 U.S.C. 371 page 3 in duplicate (4 pp.);
- 4. Application Data Sheet (3 pp.);
- 5. Preliminary Amendment (9 pp.) and Appendices (6 pp.);
- 6. ORIGINAL Statement Accompanying Sequence Listing (1 pg.);
- 7. ORIGINAL Sequence Listing (6 pp.);
- 8. ORIGINAL Computer-Readable Form of Sequence Listing (1 diskette);
- 9. Statement Accompanying Substitute Sequence Listing (1 pg.);
- 10. PAPER COPY Substitute Sequence Listing (6 pp.);
- 11. SUBSTITUTE Computer-Readable Form of Sequence Listing (1 diskette);
- 12. COPY Assignment from Parent (7 pp.);
- 13. Information Disclosure Statement, including Form 08a and b (4 pp.);
- 14. International Search Report Form PCT/ISA/210 (5 pp.);
- 15. COPY References B1 and C1-C6 cited in International Search Report; and
- 16. Return Receipt Postcard.

A copy of these papers from the file of this application is attached.

I hereby declare that all statements made herein of my own whowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application of any patent issuing thereon.

Linda M. Ginsberg

(type or print name of person certifying)

Date: May 11, 2006

10/579007

### AP20Rec'd PCT/PTO 11 MAY 2006

# BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE UNITED STATES PATENT AND TRADEMARK OFFICE

## LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)

Leena H. Karttunen is hereby given limited recognition under 37 CFR §11.9(b) as an employee of Nixon Peabody LLP, to prepare and prosecute patent applications wherein the patent applicant is the client of Nixon Peabody LLP and an attorney or agent of record in the applications is a registered practitioner who is a member of Nixon Peabody LLP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Leena H. Karttunen ceases to lawfully reside in the United States, (ii) Leena H. Karttunen's employment with Nixon Peabody LLP ceases or is terminated, or (iii) Leena H. Karttunen ceases to remain or reside in the United States on an H-1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Limited Recognition No. <u>L0207</u> Expires: February 11, 2007

Harry I. Moatz

Director of Enrollment and Discipline